作者 | 彭倩 编辑 | 乔芊 大厂"AI to C"的入口之战打得焦灼之际，蚂蚁也大手笔入场。 蚂蚁集团近日将旗下的AI健康 APP「AQ」改名为更接地气的「蚂蚁阿福」，新版本还将以"健康陪伴"为核心功能，也提供"健康问答"、"健康服务"，将服 务范围从医疗扩张至健康领域。全新升级的蚂蚁阿福是一个亲切的男医生形象，还找来何炅做代言人。 蚂蚁10多年来积累的医疗服务能力，要通过AI的方式重做一遍。 蚂蚁阿福这轮升级有两个关键转变：从医疗到健康，从 AI 工具到 AI 朋友。关于后者，张俊杰（花名：伟鹤）等蚂蚁阿福高管认为，不同于蚂蚁从前推出 的诸多AI医疗产品，拟人化的蚂蚁阿福更像朋友，这在于移动互联网的时代产品和AI时代产品天然就应该长得不一样，要从"你问我答"到"主动关怀"。 蚂蚁阿福也并非抱着要取代医生的野心，而是希望"打辅助"，通过 AI 来简化普通老百姓看病的流程，也为医生减负。同时将"健康陪伴"作为核心定位，是 希望蚂蚁阿福"能让用户不生病"，不用动用医疗资源，因为用户预防疾病的需求其实相当旺盛。 09:18 4 ... 阿福 8 智能体 Cx Hello~ + 心睛自然身体好 l 我的健康 六万 ...

Group 1 - A-shares and Hong Kong stocks experienced a significant rebound, with the Shanghai Composite Index rising by 1.19% and the Hang Seng Index increasing by 0.92% [1] - The largest medical ETF in the market (512170) and the only drug ETF (562050) both rose over 1%, indicating a broad recovery in the medical sector [1] - The medical ETF (512170) showed a strong technical signal with a "bullish engulfing" pattern, suggesting a potential trend reversal [1] Group 2 - The pharmaceutical sector in A-shares also saw a surge, with the drug ETF (562050) rising by 1.19%, driven by contributions from innovative and traditional Chinese medicine stocks [3] - The drug ETF (562050) has approximately 25% weight in traditional Chinese medicine, which helps mitigate the volatility of the overall pharmaceutical index [3] Group 3 - The Hong Kong innovation drug sector is showing signs of recovery, with the Hong Kong innovation drug ETF (520880) successfully closing in the green, attracting "bottom-fishing" funds [5] - The fund size of the Hong Kong innovation drug ETF (520880) reached a new high of 4.172 billion shares, reflecting strong investor interest [5] Group 4 - The A+H pharmaceutical sector has been in a correction phase for three months, and analysts suggest that this may be an opportune time for medium to long-term investments in pharmaceutical assets [8] - Recent positive developments in the pharmaceutical industry include overseas collaborations and increasing demand for CXO services, indicating a favorable outlook for the sector [9] Group 5 - The fund manager of the Hong Kong innovation drug ETF (520880) maintains a balanced allocation strategy, highlighting the potential for recovery in the innovative drug industry and related sectors [10] - New investment tools, such as the Hong Kong medical ETF (159137), are being launched to track the medical innovation theme, covering various core leaders in the medical field [7]

Core Insights - Baidu has launched the "Wenxin Health Steward," an upgraded version of the "Baidu Health AI Steward," along with the Atomic Open Plan and Dr.Flow creation platform [1] - The service has achieved over 47 million total orders since its launch on October 18, demonstrating a tenfold increase in scale compared to previous human-only services [1] - The evolution from a health assistant to a 24/7 "all-around family doctor" reflects significant advancements in AI capabilities [1] Group 1 - The Wenxin Health Steward is built on a vast authoritative data knowledge system, including 16 million pieces of professional science and journal data, 3 million multimodal medical imaging materials, and over 100 million diagnostic logic data points [1] - The system supports real-time consultations with over 10,000 authoritative AI doctor avatars and direct connections to 360,000 practicing doctors in public hospitals [1] - It can accurately recognize various input forms such as text, voice, and images, achieving an accuracy rate of over 95% [1] Group 2 - The Wenxin Health Steward will introduce features like full-duplex digital human video follow-ups and multidisciplinary consultation group chats [1] - These features aim to provide proactive management services, including active follow-ups from top-tier doctors and online collaborative diagnosis among specialists [1]

能源金属拉升 能源金属拉升，盛新锂业、天齐锂业、融捷股份、赣锋锂业涨幅靠前。 消息面上，碳酸锂期货主力合约盘中涨超6%，碳酸锂2602购106000期权合约暴涨116.84%，从昨收价 1900涨至4120；碳酸锂2602购108000期权合约暴涨115.15%，从昨收价1650涨至3550；碳酸锂2602购 104000期权合约暴涨114.35%，从昨收价2300涨至4930。 AI医疗活跃 12月17日，A股三大股指小幅高开走窄幅震荡，午后强力拉升，截止收盘，沪指涨1.19%报3870.28点， 深成指涨2.4%报13224.51点，创业板指涨3.39%报3175.91点，科创50指数涨2.47%报1325.33点。全市场 成交额1.83万亿元，超3600股上涨。 盘面上，算力硬件概念表现活跃，中瓷电子、环旭电子等多股涨停，"易中天"光模块三巨头大涨；锂电 产业链走强，金圆股份4天2板，天际股份涨停；液冷概念爆发，奕东电子、英维克等多股涨停，荣亿精 密'华光新材均涨近19%；大金融方向午后发力，华泰证券盘中一度逼近涨停，中国太保涨超4%；氟化 工、F5G、麒麟电池及铜缆高速连接等板块涨幅居前。海南板块逆市 ...

Market Analysis - The market is experiencing a significant downturn, with over 90% of trading days showing more than 4,000 stocks declining, indicating a stampede phenomenon [2] - There is a lack of clear support from major funds, and small-cap stocks are showing notably weaker performance [2] - The upcoming annual report disclosures are raising caution, particularly for ST stocks and underperforming stocks [2] Industry Insights - The introduction of national policies is positively impacting the non-ferrous metals industry, with the "Non-Ferrous Metals Industry Stabilization and Growth Work Plan (2025-2026)" aimed at promoting high-quality development and enhancing supply chain resilience [2] - The second half of the year remains in a loose monetary cycle, with some metal fundamentals trending positively, suggesting a potential rise in non-ferrous metal prices [2] - The focus for next year will shift from interest rate cuts to growth in industrial demand, providing a fundamental support for the sector [2] Stock Performance - The three major indices opened mixed, with over 3,000 stocks declining at the start of trading [3] - The tungsten market is experiencing a rapid price increase, with tungsten concentrate prices exceeding 400,000 yuan per ton and APT prices surpassing 600,000 yuan per ton [3] AI and Nuclear Fusion Sectors - The AI healthcare sector is seeing significant activity, with companies like Meian Health reaching a trading limit, indicating strong market interest [4] - The nuclear fusion sector is also gaining traction, with multiple projects announced, totaling over 2.4 billion yuan in contracts [4] Market Predictions - The Shanghai Composite Index appears to have halted its decline, but the trading volume remains low, indicating a weak market sentiment [6] - The ChiNext Index is stabilizing near the 20-day moving average, with a critical support level at 3,080 points [6] - Without protective measures or significant recovery in external markets, the likelihood of further index declines is high [6] Investment Opportunities - Foreign institutions are optimistic about China's assets for 2026, citing profit growth and innovation as key drivers for a rebound [13] - Long-term foreign capital has shown a positive inflow into the Chinese stock market, contrasting with previous outflows [13] - The non-ferrous metals sector is expected to benefit from structural opportunities, particularly in copper and aluminum, driven by industrial demand [13] Economic Context - The Federal Reserve's recent interest rate cut and plans to purchase short-term government bonds have led to a decline in the dollar index, positively affecting non-ferrous metal prices [14] - The ongoing bull market for base metals is supported by supply constraints and rising prices for metals like silver and copper [14] Strategic Focus - The non-ferrous metals industry is positioned as a key area for investment, particularly in the context of technological advancements and the "anti-involution" policy [15] - The sector is characterized by stable demand across various industries, making it less susceptible to economic cycles [15] - Investing in undervalued non-ferrous metal companies can provide significant upside potential, especially during inflationary periods [15]

Group 1 - The pharmaceutical and biotechnology industry in China is expected to show multiple positive signals by 2025, with the market size projected to exceed 400 billion yuan in 2024, and 113 domestic innovative drugs approved during the "14th Five-Year Plan" period, which is 2.8 times that of the "13th Five-Year Plan" period [1] - The total amount of License-out projects for innovative drugs has reached a new record, with preclinical projects accounting for 68%, indicating that Chinese innovative drugs are gradually gaining global recognition [1] - The chemical pharmaceutical sector is leading the market driven by innovative drugs and AI healthcare, with the pharmaceutical sector's valuation approaching the historical average over the past 10 years, and public fund holdings showing a quarterly increasing trend [1] Group 2 - In the medical device sector, the bidding market size in Q3 2025 is expected to grow by 29.8% year-on-year, with revenue turning points emerging for medical device companies, driven by continuous demand release from equipment renewal policies [1] - The brain-computer interface field is accelerating development under policy support, with national and local governments expected to introduce supportive policies in 2025, and global companies like Neuralink driving technological iteration and clinical applications [1] - The industry is facing a transformation in the payment system, with significant growth potential for commercial health insurance, which is expected to promote the transition of innovative drug payments from a "single" to a diversified payment model [1] Group 3 - The Guotai Innovative Drug ETF (517110) tracks the SHS Innovative Drug Index (931409), which selects listed companies involved in the research and development of chemical and biological drugs from the Shanghai, Hong Kong, and Shenzhen markets to reflect the overall performance of the innovative drug sector [2] - The index consists of 50 constituent stocks, indicating a high industry concentration, focusing on innovative drug companies with growth potential and research-driven characteristics [2]

12月16日，医渡科技(02158)发布公告显示，当日以每股4.94港元的价格回购约64万股，回购金额约320 万港元。12月以来，公司已回购8次，累计回购约275万股，总金额约1400万港元。 光大证券在跟踪研报中指出，公司近期在AI医疗创新落地方面取得多项进展，包括深度参与北京市医 疗领域国家人工智能应用中试基地、中标III期临床研究项目、新增河北和广州两地"惠民保"业务。报告 认为，其医疗大模型已初步构建"数据-算法-场景"闭环，推动业务在多场景中持续落地。 密集回购背后，是公司对自身价值的坚定认可，更依托业绩改善与业务拓展的双重支撑。医渡科技2026 财年中期业绩盈利质量与运营效率实现关键突破，现有业务经调整EBITDA约5400万元，较去年同期翻 倍，会计报表层面几近盈亏平衡。 另外值得关注的是，公司创始人、董事长宫如璟女士近日获聘香港城市大学数码医学研究院顾问委员会 成员，将作为连接产业实践与学术研究的关键桥梁角色，促进产学研融合向更高层次、更实质性的阶段 迈进，为行业创新生态构建注入新动能。 ...

另外值得关注的是，公司创始人、董事长宫如璟女士近日获聘香港城市大学数码医学研究院顾问委员会 成员，将作为连接产业实践与学术研究的关键桥梁角色，促进产学研融合向更高层次、更实质性的阶段 迈进，为行业创新生态构建注入新动能。 智通财经APP获悉，12月16日，医渡科技(02158)发布公告显示，当日以每股4.94港元的价格回购约64万 股，回购金额约320万港元。12月以来，公司已回购8次，累计回购约275万股，总金额约1400万港元。 密集回购背后，是公司对自身价值的坚定认可，更依托业绩改善与业务拓展的双重支撑。医渡科技2026 财年中期业绩盈利质量与运营效率实现关键突破，现有业务经调整EBITDA约5400万元，较去年同期翻 倍，会计报表层面几近盈亏平衡。 光大证券在跟踪研报中指出，公司近期在AI医疗创新落地方面取得多项进展，包括深度参与北京市医 疗领域国家人工智能应用中试基地、中标III期临床研究项目、新增河北和广州两地"惠民保"业务。报告 认为，其医疗大模型已初步构建"数据-算法-场景"闭环，推动业务在多场景中持续落地。 ...

文 | 快刀财经 朱末 资本寒冬中，活下去比活得好更重要。 2025年12月5日，香港上市公司国锐生活官宣以总计2.69亿元人民币（现金及股票），收购春雨医生78.29%的股权，成为其控股股东。春雨医生最终出售对 价约为3.4亿元人民币，与昔日的70亿元估值相比，仅有巅峰时期的二十分之一。 创业十四年，春雨医生选择以"被并购"为过去的创业旅途画上句号。交易完成后，国锐生活这家以物业管理为主业的公司，将成为中国移动医疗开创者的控 股股东，从收购角度来看，春雨医生拥有成熟的产业体系、稀缺的医疗资源以及已验证的商业闭环，可以降低传统房地产周期风险，重塑整体竞争力。 而对于春雨医生来说，这已经算是最好的归宿。早在去年，春雨医生就已在行业内寻求买家，接触过京东、百度等互联网大厂，但因为春雨医生要价过高未 能成交。 作为最早探路线上问诊的互联网医疗企业，春雨是当之无愧的行业"独角兽"，一手开创了中实时问诊模式，点燃了中国互联网医疗的星星之火，医疗圈内都 视春雨为绝对的行业大哥，纷纷进行效仿。 然而，创始人张锐的猝然离世，使得春雨医生分拆打包上市的计划被搁置，在很长一段时间内陷入战略迷茫，自此由盛转衰，再传出消息，已经"物 ...

从资金流向上来看，当日AI医疗板块主力资金净流出8252.25万元，游资资金净流出8136.03万元，散户 资金净流入1.64亿元。AI医疗板块个股资金流向见下表： 证券之星消息，12月16日AI医疗板块较上一交易日下跌0.98%，思创医惠领跌。当日上证指数报收于 3824.81，下跌1.11%。深证成指报收于12914.67，下跌1.51%。AI医疗板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...